CN100352497C - 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 - Google Patents

应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 Download PDF

Info

Publication number
CN100352497C
CN100352497C CNB200410078988XA CN200410078988A CN100352497C CN 100352497 C CN100352497 C CN 100352497C CN B200410078988X A CNB200410078988X A CN B200410078988XA CN 200410078988 A CN200410078988 A CN 200410078988A CN 100352497 C CN100352497 C CN 100352497C
Authority
CN
China
Prior art keywords
cell
antibody
cd40cr
mice
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200410078988XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1757413A (zh
Inventor
R·J·诺伊勒
C·M·伯恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of CN1757413A publication Critical patent/CN1757413A/zh
Application granted granted Critical
Publication of CN100352497C publication Critical patent/CN100352497C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CNB200410078988XA 1998-04-03 1999-04-02 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 Expired - Fee Related CN100352497C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
US09/054488 1998-04-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB998067563A Division CN1173735C (zh) 1998-04-03 1999-04-02 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用

Publications (2)

Publication Number Publication Date
CN1757413A CN1757413A (zh) 2006-04-12
CN100352497C true CN100352497C (zh) 2007-12-05

Family

ID=21991433

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB200410078988XA Expired - Fee Related CN100352497C (zh) 1998-04-03 1999-04-02 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫
CNB998067563A Expired - Fee Related CN1173735C (zh) 1998-04-03 1999-04-02 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB998067563A Expired - Fee Related CN1173735C (zh) 1998-04-03 1999-04-02 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用

Country Status (9)

Country Link
EP (1) EP1067954A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002510643A (cg-RX-API-DMAC7.html)
KR (1) KR20010072564A (cg-RX-API-DMAC7.html)
CN (2) CN100352497C (cg-RX-API-DMAC7.html)
AU (1) AU743824B2 (cg-RX-API-DMAC7.html)
HU (1) HUP0101689A3 (cg-RX-API-DMAC7.html)
NO (1) NO20004966L (cg-RX-API-DMAC7.html)
TW (1) TWI224969B (cg-RX-API-DMAC7.html)
WO (1) WO1999051258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1996023071A2 (en) * 1995-01-26 1996-08-01 Bristol-Myers Squibb Company MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
CN1572325A (zh) * 1997-01-10 2005-02-02 拜奥根Idec马萨诸塞公司 用抗cd40l化合物治疗狼疮性肾炎
WO1998039026A2 (en) * 1997-03-07 1998-09-11 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
WO1996023071A2 (en) * 1995-01-26 1996-08-01 Bristol-Myers Squibb Company MONOCLONAL ANTIBODIES SPECIFIC FOR DIFFERENT EPITOPES OF HUMAN gp39 AND METHODS FOR THEIR USE IN DIAGNOSIS AND THERAPY

Also Published As

Publication number Publication date
KR20010072564A (ko) 2001-07-31
TWI224969B (en) 2004-12-11
AU3379699A (en) 1999-10-25
CN1173735C (zh) 2004-11-03
JP2002510643A (ja) 2002-04-09
HUP0101689A3 (en) 2004-08-30
CN1303301A (zh) 2001-07-11
EP1067954A4 (en) 2004-08-18
EP1067954A1 (en) 2001-01-17
AU743824B2 (en) 2002-02-07
NO20004966D0 (no) 2000-10-02
HUP0101689A2 (hu) 2001-08-28
CN1757413A (zh) 2006-04-12
NO20004966L (no) 2000-12-04
WO1999051258A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
JP4148537B2 (ja) Cd40crレセプター及びそれに対するリガンド
Daridon et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome
CN104619722B (zh) 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
AU2013312211B2 (en) VISTA modulators for diagnosis and treatment of cancer
Contin et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients
TWI222453B (en) Ligand for herpes simplex virus entry mediator and methods of use
EA015351B1 (ru) Антагонисты il-17a и il-17f и способы их применения
Zone et al. IgA autoimmune disorders: development of a passive transfer mouse model
Segal et al. The subclass specificity for the binding of murine myeloma proteins to macrophage and lymphocyte cell lines and to normal spleen cells
ES2747920T3 (es) Anticuerpo anti-NKP46 para diagnóstico de un linfoma de células T periféricas no cutáneo (PTCL)
JPS62116599A (ja) 医薬組成物
JPH09502708A (ja) Il4により伝達される疾患の治療に有用な組み換え型il4抗体
EP0872488B1 (en) MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME
US20080254033A1 (en) Pharmaceutical Compositions Containing Antagonists to Lrp4, Lrp8 or Megalin for Treatment of Diseases
CN106573976A (zh) 抗cd84抗体、包含所述抗体的组合物及其用途
US20230014398A1 (en) Anti-b7-h3 monoclonal antibody and methods of use thereof
Hoshino et al. Cell kinetic analysis of human brain tumors by in situ double labelling with bromodeoxyuridine and iododeoxyuridine
US20220389106A1 (en) Anti-epha10 antibodies and methods of use thereof
US6472510B1 (en) CD40 receptor ligands
Takayama et al. Antigen-specific directional target cell lysis by perforin-negative T lymphocyte clones
AU743824B2 (en) Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
Ronda et al. Anti-fibroblast antibodies in systemic sclerosis
US20020058037A1 (en) Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease
HK1067887A (en) Antibodies that bind the cd40cr receptor
HOSHIN04 et al. Publlcatlon zyxwvutsrqponml

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071205